RNA Therapies: when the copy is better than the original
Supervisors: Simone Baldovino, Elisa Menegatti, Dario Roccatello, Savino Sciascia.
Date: 15 October 2022
Description
Research on mRNA therapies has made great strides in the last decade, as the example of the two main vaccines used for SARS-CoV-2 shows. In this interview with the ‘Rivista italiana di Malattie Rare’ (Italian Journal of Rare Diseases), we report how, in addition to their use for vaccination purposes, other uses of mRNAs for the treatment of post-infarct lesions, various cancers and some rare diseases such as methylmalonic aciduria, urea cycle disorders, cystic fibrosis and myasthenia gravis are also under investigation.